RecruitingMacular DegenerationAge-Related Macular DegenerationChoroidal Neovascularization

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

Eligible age

50+ yrs

Accepts

All genders

Locations

26 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD. The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.

Sponsor: EyeBiotech Ltd.